Amrita Jain
Private Equity Investor bij LongeVC
Profiel
Amrita Jain is Principle at LongeVC, a venture capital company backing visionary biotech.
Before joining LongeVC, Amrita worked at Fusix Biotech, a pre-clinical-stage biotechnology company developing a next-generation oncolytic virus platform to treat patients across multiple tumour types.
She was also a Business Development Manager for cancer immunotherapy company Immatics Biotechnologies and an Investment Analyst at venture capital fund Life Science Partners ( LSP).
Amrita holds a Master's degree in Genome Sciences/Genomics from Madurai Kamaraj University and a PhD in Biochemistry and Molecular Biology from the University of Utrecht.
Actieve functies van Amrita Jain
Bedrijven | Functie | Begin |
---|---|---|
LongeVC
LongeVC Investment ManagersFinance LongeVC is a venture capital firm, founded in 2020 by Garri Zmudze, Ilya Suharenko, Sergey Jakimov. The firm is headquartered in Lugano, Switzerland. | Private Equity Investor | 01-03-2021 |
Eerdere bekende functies van Amrita Jain
Bedrijven | Functie | Einde |
---|---|---|
Fusix Biotech GmbH
Fusix Biotech GmbH BiotechnologyHealth Technology Fusix Biotech GmbH is a private company located in Germany that aims to deliver breakthrough cancer immunotherapies utilizing a unique "fusogenic" mechanism of action to directly kill tumor cells, heat up the tumor microenvironment, and mediate systemic immune effects to target tumor cells throughout the body. The German company is still part of the Klinikum rechts der Isar of the Technical University Munich and is currently planning to spin-out in 2022. The Fusix technology offers a unique mechanism of action that will revolutionize immune oncology in solid cancers by converting the tumor microenvironment from an immune suppressed “cold” tumor into an immune-sensitized “hot” tumor infiltrated with immunotherapeutics. | Corporate Officer/Principal | 30-04-2022 |
LSP Services Deutschland GmbH | Private Equity Analist | 28-02-2020 |
Bavarian Nordic GmbH
Bavarian Nordic GmbH BiotechnologyHealth Technology Part of Bavarian Nordic A/S, Bavarian Nordic GmbH engages in research and development in biotechnology for cancer and infectious diseases. The company is based in Martinsried, Germany. The German company was founded in 2014. Paul Chaplin has been the CEO of the company since 1999. | Corporate Officer/Principal | 01-01-2019 |
Opleiding van Amrita Jain
University of Utrecht | Doctorate Degree |
Madurai Kamaraj University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
LSP Services Deutschland GmbH | Finance |
LongeVC
LongeVC Investment ManagersFinance LongeVC is a venture capital firm, founded in 2020 by Garri Zmudze, Ilya Suharenko, Sergey Jakimov. The firm is headquartered in Lugano, Switzerland. | Finance |
Fusix Biotech GmbH
Fusix Biotech GmbH BiotechnologyHealth Technology Fusix Biotech GmbH is a private company located in Germany that aims to deliver breakthrough cancer immunotherapies utilizing a unique "fusogenic" mechanism of action to directly kill tumor cells, heat up the tumor microenvironment, and mediate systemic immune effects to target tumor cells throughout the body. The German company is still part of the Klinikum rechts der Isar of the Technical University Munich and is currently planning to spin-out in 2022. The Fusix technology offers a unique mechanism of action that will revolutionize immune oncology in solid cancers by converting the tumor microenvironment from an immune suppressed “cold” tumor into an immune-sensitized “hot” tumor infiltrated with immunotherapeutics. | Health Technology |
Bavarian Nordic GmbH
Bavarian Nordic GmbH BiotechnologyHealth Technology Part of Bavarian Nordic A/S, Bavarian Nordic GmbH engages in research and development in biotechnology for cancer and infectious diseases. The company is based in Martinsried, Germany. The German company was founded in 2014. Paul Chaplin has been the CEO of the company since 1999. | Health Technology |